HPV vaccination according to Recommended Adult Immunization Schedule, United States, 2020

4 فوریه 2020

In October 2018, the U.S. Food and Drug Administration expanded the approved age range for 9vHPV use from 9 through 26 years to 9 through 45 years in women and men (www.fda.gov/media/90064/download). After reviewing evidence related to HPV vaccination of adults, in June 2019, ACIP updated recommendations for catch-up vaccination and for vaccination of adults older than the recommended catch-up age.

ACIP does not recommend catch-up HPV vaccination for all adults older than age 26 years. Instead, shared clinical decision-making regarding HPV vaccination is recommended for some adults age 27 through 45 years who are not adequately vaccinated.

For these adults, clinicians can consider discussing HPV vaccination with persons who are most likely to benefit, using the following considerations:

HPV is a very common sexually transmitted infection. Most HPV infections are transient and asymptomatic and cause no clinical problems.

Although new HPV infections are most commonly acquired in adolescence and young adulthood, some adults are at risk for new HPV infections. At any age, having a new sex partner is a risk factor for acquiring a new HPV infection.

Persons who are in a long-term, mutually monogamous sexual partnership are not likely to acquire a new HPV infection.

Most sexually active adults have been exposed to some HPV types, although not necessarily all of the HPV types targeted by vaccination.

No clinical antibody test can determine whether a person is already immune or still susceptible to any given HPV type.

HPV vaccine efficacy is high among persons who have not been exposed to vaccine-type HPV before vaccination.

Vaccine effectiveness might be low among persons with risk factors for HPV infection or disease (e.g., adults with multiple lifetime sex partners and likely previous infection with vaccine-type HPV), as well as among persons with certain immunocompromising conditions.

HPV vaccines are prophylactic (i.e., they prevent new HPV infections). They do not prevent progression of HPV infection to disease, decrease time to clearance of HPV infection, or treat HPV-related disease.

:   Reference


Recommended Adult Immunization Schedule, United States, 2020